Prakriti-Based Differences in Drug Response: Pharmacogenomic Evidence from Indian Clinical Trials

Dr. Meera Iyer — Tue, 28 Jul 2026 06:00:00 +0000

When Ancient Constitutional Classification Meets Modern Genomics

Pharmacogenomics studies how a person’s DNA can influence medication response, including differences in drug metabolism, therapeutic effect, adverse reactions, and dose requirements. From an Ayurvedic perspective, its closest point of contact is deha prakriti, the constitutional assessment of an individual through stable physical, physiological, and psychological tendencies.

The most useful way to frame the intersection is not to equate a dosha directly with a gene. Rather, prakriti can be understood as a structured phenotypic classification that may help stratify people into biologically meaningful groups. Published work in ayurgenomics has explored whether Vata, Pitta, and Kapha-predominant individuals differ in gene expression, CYP2C19 polymorphisms, DNA methylation, HLA markers, and genome-wide SNP patterns. The clinical promise is personalization; the clinical caution is that prakriti assessment is not a substitute for formal pharmacogenomic testing or medical judgment.

The Foundational Hypothesis: Prakriti as a Phenotypic Framework

Classical Ayurveda describes prakriti as the natural constitution of a person, shaped by dosha predominance and expressed through anatomical build, appetite, digestion, bowel pattern, skin and hair features, heat or cold tolerance, sleep, activity, temperament, disease resistance, and other long-term traits. The classical framework includes seven prakriti categories: Vata, Pitta, Kapha, Vata-Pitta, Vata-Kapha, Pitta-Kapha, and balanced samadoshaja prakriti.

Ayurvedic texts place the formation of constitution at the beginning of life, using ideas such as the union of paternal and maternal reproductive factors, the condition of the uterus, time, maternal diet and lifestyle, and the predominance of dosha. This makes prakriti broader than genotype alone: it is closer to a constitutional phenotype that includes inherited, developmental, metabolic, and behavioral expression.

Prakriti Type	Classical Ayurvedic Characteristics	Molecular Domains Explored in Published Work	Appropriate Interpretation
Vata	Lighter or less-developed body build, variable appetite and bowel habits, quick activity, dry skin or hair, sensitivity to cold, quick grasp with lower retention.	Gene-expression differences, DNA methylation patterns, and HLA-related classification have been examined in prakriti-stratified cohorts.	Useful as a constitutional phenotype in exploratory research; not a stand-alone predictor of drug dose.
Pitta	Moderate build, strong appetite and thirst, higher heat and perspiration tendency, sharper digestion, skin pigmentation features, and lower tolerance of heat.	CYP2C19 extensive-metabolizer genotype was reported as predominant in Pitta in one CYP2C19 study; a genome-wide SNP study associated Pitta with PGM1, a gene involved in metabolic pathways.	Supports the classical link between Pitta and metabolism as a research hypothesis; clinical medication choices still require standard medical assessment.
Kapha	Heavier or well-developed build, lower appetite and slower digestion, steadier activity, good memory retention, oily skin tendency, calm temperament, and stronger endurance.	CYP2C19 poor-metabolizer genotype was highest in Kapha in one study; DNA methylation work reported Kapha-associated methylation patterns and a CDH22 signal linked with BMI.	Suggests a possible biological layer to Kapha-associated metabolic traits; it does not justify higher or lower medication dosing by itself.

Published Human Studies Connecting Prakriti and Molecular Variation

The strongest material for this topic comes from small but influential human studies that used prakriti classification as a stratification method. These papers are best read as early translational research: they help define questions for personalized medicine, but they do not create a clinical dosing system.

Prasher et al. (2008): Gene Expression and Biochemical Correlates

Prasher and colleagues published “Whole genome expression and biochemical correlates of extreme constitutional types defined in Ayurveda” in the Journal of Translational Medicine. The study screened volunteers through prakriti assessment and selected 96 unrelated, ethnically matched healthy individuals classified as Vata, Pitta, or Kapha predominant. The work compared biochemical, hematological, and genome-wide expression patterns among these groups.

The study selected 39 Vata, 29 Pitta, and 28 Kapha individuals after broader screening.
The authors reported prakriti-linked differences in biochemical and hematological parameters.
They reported 159 differentially expressed annotated genes in males and 92 in females, with limited overlap between the sex-stratified gene sets.
The functional categories included transport, immune response, regulation of blood coagulation, and regulation of cyclin-dependent protein kinase activity.
The study described itself as an early attempt to connect Ayurvedic phenotyping with modern biological measures.

This paper remains important because it treated prakriti as a reproducible phenotype rather than as a loose descriptive label. Its value for pharmacogenomics is indirect: it suggests that constitutional grouping may capture molecular differences relevant to metabolism and immune response, while leaving drug-specific decisions to future validation.

Ghodke, Joshi and Patwardhan (2011): CYP2C19 and Metabolic Variability

Ghodke, Joshi and Patwardhan examined CYP2C19 polymorphisms in 132 unrelated healthy subjects classified by prakriti. CYP2C19 is a clinically relevant drug-metabolizing enzyme, and the study directly addressed the Ayurvedic idea that Pitta and Kapha differ in metabolic tendency.

The authors genotyped CYP2C19 using PCR-RFLP.
The extensive-metabolizer genotype was reported as predominant in Pitta, with 91% of Pitta individuals in that category.
The poor-metabolizer genotype was reported as highest in Kapha, at 31%, compared with 12% in Vata and 9% in Pitta.
The CYP2C19 *2/*3 poor-metabolizer genotype was significantly associated with Kapha in the study population.

This is the most directly pharmacogenomic paper in the prakriti literature. It supports a focused research question: whether standardized prakriti assessment can enrich or stratify cohorts for CYP-related variability. It does not make prakriti a replacement for CYP2C19 genotyping when a medication decision requires pharmacogenomic evidence.

Rotti et al. (2015): DNA Methylation Signatures

Rotti and colleagues examined DNA methylation in phenotype-stratified Indian subjects. After a larger prakriti assessment process, the study analyzed 147 healthy male individuals aged 20–30 years who were classified into Vata, Pitta, or Kapha groups.

The authors reported differentially methylated regions in CpG islands, CpG shores, promoters, untranslated regions, and gene bodies.
Pitta showed distinct promoter and gene-body methylation signals.
Vata and Kapha groups also showed prakriti-associated methylation patterns.
The study validated selected genes including LHX1 for Vata, SOX11 for Pitta, and CDH22 for Kapha.
CDH22 was discussed in relation to BMI in the Kapha group.

This work adds an epigenomic layer to the ayurgenomics discussion. It is especially relevant because prakriti is described in Ayurveda as a stable constitutional pattern, while methylation reflects regulation of gene expression rather than only fixed DNA sequence.

Govindaraj et al. (2015): Genome-Wide SNP Analysis and PGM1

Govindaraj and colleagues published a genome-wide SNP analysis correlating Ayurveda prakriti in Scientific Reports. The study began with 3,416 assessed individuals and used 262 well-classified male subjects for genome-wide analysis with Affymetrix 6.0 arrays.

The authors used genome-wide SNP data to examine differences among Vata, Pitta, and Kapha groups.
They reported 52 markers for genotype-phenotype correlation and 28 genic SNPs among the relevant markers.
A notable association was reported between Pitta prakriti and PGM1.
PGM1 is involved in metabolic pathways such as glycolysis, gluconeogenesis, galactose metabolism, purine metabolism, and starch and sucrose metabolism.

The PGM1 finding is meaningful because Pitta is classically linked with digestion, transformation, heat, and metabolism. The proper interpretation is a biologically plausible correlation within a defined study design, not a universal genetic definition of Pitta.

Clinical Implications: A Research Bridge, Not a Stand-Alone Dosing System

The practical attraction of prakriti-guided personalization is clear: Ayurveda already uses constitutional assessment to individualize diet, lifestyle, herbs, therapies, and preventive guidance. Pharmacogenomics similarly seeks to individualize care by identifying genetic variation that affects medication response. The responsible bridge between the two is to use prakriti as a phenotyping layer that may help generate, refine, or test personalized-medicine hypotheses.

In routine medical care, however, medication decisions must not be made from prakriti alone. CYP2C19, for example, is relevant to medicines such as proton pump inhibitors, clopidogrel, and some antidepressants, but clinical interpretation depends on the specific drug, the patient’s genotype, diagnosis, age, organ function, other medicines, treatment goal, and prescribing guidance. Prakriti may eventually help identify who should be prioritized for formal testing or closer monitoring, but the current role is supportive and investigational.

How Prakriti Could Assist Personalization

A careful prakriti-informed model would keep Ayurvedic constitution and modern pharmacogenomics in their proper domains. Prakriti can organize whole-person traits, while pharmacogenomic testing can identify specific genetic variants relevant to particular drugs.

Use Case	Current Status	Practical Meaning
Constitutional assessment for diet, lifestyle, digestion, sleep, endurance, and preventive care	Established within Ayurvedic clinical reasoning	Can be used by qualified Ayurvedic practitioners as part of individualized care.
Stratifying participants in genomics, epigenomics, metabolomics, and pharmacogenomics studies	Supported by exploratory human studies	May reduce biological heterogeneity and produce clearer research questions.
Identifying people who may benefit from formal pharmacogenomic testing	Promising but not validated for routine clinical use	Could become useful if large prospective studies show added predictive value.
Choosing or changing a drug dose from prakriti alone	Not appropriate for routine care	Medication decisions should follow physician guidance, labeling, clinical pharmacology, and formal pharmacogenomic results when indicated.

A Prakriti-Informed Research Framework

The most rigorous path is to test prakriti alongside established clinical and genomic variables instead of treating it as a replacement for them. A future study design could combine standardized prakriti assessment, blinded practitioner evaluation, ancestry and demographic data, diet and lifestyle records, laboratory measures, pharmacogenomic panels, and prospective treatment outcomes.

Use validated prakriti questionnaires and independent clinician assessment to reduce classification error.
Record age, sex, ancestry, region, diet, disease status, organ function, and concurrent medicines.
Genotype clinically relevant pharmacogenomic markers, including CYP enzymes where appropriate.
Follow medication response, adverse effects, dose adjustments, and treatment outcomes prospectively.
Measure whether prakriti adds predictive value beyond standard pharmacogenomic and clinical variables.

This framework preserves the Ayurvedic insight that patients differ constitutionally while respecting the modern requirement that drug-specific decisions need drug-specific evidence.

Limitations and Necessary Caution

The prakriti-genomics field is intellectually important, but the current human literature is still early-stage. Its findings are best used to shape further research and not to create simplified rules such as “Vata needs one dose,” “Pitta needs another,” or “Kapha needs a higher dose.”

Sample size: The major studies used carefully selected cohorts such as 96 subjects, 132 subjects, 147 male subjects, or 262 male subjects. These are valuable for hypothesis formation, but not enough for broad clinical rules.
Population specificity: Several cohorts were drawn from specific Indian populations and may not generalize to every region, ancestry group, age group, or mixed-prakriti population.
Classification complexity: Prakriti assessment includes many traits and can vary by tool, practitioner, and the dominance of single or mixed dosha patterns.
Probabilistic associations: A group-level association does not determine an individual person’s CYP status, adverse-effect risk, or medication response.
Holistic versus single-gene mapping: Prakriti is a multi-dimensional constitutional framework, while pharmacogenomic markers are often drug- and pathway-specific.

These limitations do not weaken the value of the research direction; they define the discipline needed to move from correlation to clinical usefulness.

The Path Forward

Ayurgenomics can mature by combining classical Ayurvedic phenotyping with modern study design. The strongest future work would be multi-center, adequately powered, transparent in prakriti classification, and linked to real clinical outcomes rather than only molecular differences.

Large multi-region cohorts across diverse Indian and global populations.
Standardized prakriti tools with reproducibility testing between practitioners and questionnaires.
Integrated omics work combining genomics, transcriptomics, epigenomics, metabolomics, microbiome data, and clinical parameters.
Prospective medication-response studies for specific drugs with known pharmacogenomic relevance.
Independent replication before any prakriti-based medication guidance is used in routine care.

The meeting point of Ayurveda and pharmacogenomics is not a shortcut around modern testing; it is a possible enrichment of personalized medicine through a deep constitutional phenotype. If validated at scale, prakriti may help clinicians and researchers think about individuality in a more integrated way. For related reading, see Reverse Pharmacology in Ayurveda and Ayurvedic Herbs and Cytochrome P450 Enzymes.

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Do not start, stop, reduce, increase, or substitute any medication based on prakriti, dosha assessment, CYP status, or online information alone. Consult a licensed physician, clinical pharmacologist, qualified Ayurvedic practitioner, or other qualified healthcare provider for individualized care. Formal pharmacogenomic testing, when needed, should be ordered and interpreted by qualified professionals in the context of the specific medicine and patient.

Indian Research – Ayurved Healing